Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indraprastha MedicalBOM:532150 -1.95%81 EBITDA Margin % is 18.60% as of Mar. 2026, which is 57% above its 10-year median of 11.86. GuruFocus rates BOM:532150 with a GF Score™ of 81/100 and a GF Value™ of ₹428.14 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Indraprastha Medical ranks better than 74.74% on this metric.
Indraprastha Medical (BOM:532150) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Indraprastha Medical EBITDA Margin % Related Terms
Indraprastha Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Indraprastha Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532150 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Indraprastha Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indraprastha Medical EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Indraprastha Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Indraprastha Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indraprastha Medical (BOM:532150) has a EBITDA Margin % of 18.60% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indraprastha Medical and its competitors. This is 57% above median its historical median of 11.86. Over the past decade, Indraprastha Medical's EBITDA Margin % has ranged from 6.31 to 19.94. According to the industry distribution chart, Indraprastha Medical ranks #168 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 25.3%.
Is Indraprastha Medical's EBITDA Margin % too high?
Indraprastha Medical's current EBITDA Margin % of 18.60% is 57% above median its 10-year median of 11.86. Over the past 10 years, this metric has ranged from a low of 6.31 to a high of 19.94. The Healthcare Providers & Services industry median EBITDA Margin % is 10.23. Indraprastha Medical's value of 18.60% is 81.8% above this industry median. Based on the distribution chart, Indraprastha Medical ranks #168 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Indraprastha Medical has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Indraprastha Medical's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Indraprastha Medical ranks #168 out of 665 companies for EBITDA Margin %. This puts Indraprastha Medical in the upper half of its industry. The industry median EBITDA Margin % is 10.23. Indraprastha Medical's value of 18.60% is 81.8% above this benchmark. Historically, Indraprastha Medical's own EBITDA Margin % has ranged from 6.31 to 19.94 over the past decade. While the company's 10-year median is 11.86 vs. the industry median of 10.23, Indraprastha Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.23, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indraprastha Medical's current EBITDA Margin % of 18.60% is 81.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indraprastha Medical and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indraprastha Medical's current EBITDA Margin % is 18.60%, which is 57% above median its own 10-year median of 11.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indraprastha Medical stock overvalued right now?
Based on GuruFocus' analysis, Indraprastha Medical (BOM:532150) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹428.14, compared to a current price of ₹376.95 — trading 12% below its estimated fair value. The current EBITDA Margin % is 18.60%, which is 57% above median its 10-year median of 11.86 and 81.8% above the Healthcare Providers & Services industry median of 10.23. Indraprastha Medical's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Indraprastha Medical (BOM:532150), the current EBITDA Margin % is 18.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indraprastha Medical (BOM:532150) Overvalued in 2026?
Based on GuruFocus' analysis, Indraprastha Medical stock appears to be undervalued.
The current stock price of ₹376.95 is trading 12% below its estimated GF Value™ of ₹428.14.
GuruFocus considers Indraprastha Medical to be Modestly Undervalued.
Key valuation signals for BOM:532150:
EBITDA Margin %: 18.60% (57% above median its 10-year median of 11.86)
GF Value™: ₹428.14 vs. price of ₹376.95 (12% below fair value)
Industry Position: 81.8% above the Healthcare Providers & Services median (#168 of 665)
No single metric tells the full story. See the BOM:532150 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indraprastha Medical Corp Ltd is an Indian company that operates in the healthcare business. It offers services in the field of anaesthesiology, pediatrics, bone marrow transplant, dental surgery, neonatology, dermatology, obesity, and metabolic surgery, orthopaedics, robotic surgery, spine surgery and in many other areas. The company also provides diagnosis, treatment, and management of various hormonal disorders; and inpatient and ambulatory care services. Geographically all the business activities of the group are carried out through the regions of India. It derives revenue from the provision of services.
81GF Score
Get the complete analysis for BOM:532150
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532150 has been successfully added to your 
